[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

6 ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG

Program: Oral and Poster Abstracts
Type: Oral
Session: Plenary Scientific Session
Sunday, December 9, 2012: 3:45 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Francesco Lo-Coco, MD1, Giuseppe Avvisati, MD, PhD2*, Sonia Maria Orlando3*, Felicetto Ferrara, MD4, Marco Vignetti, MD5*, Paola Fazi, MD6*, Eros Di Bona, MD7*, Giorgina Specchia, MD8*, Simona Sica, MD9*, Mariadomenica Divona10*, Alessandro Levis, MD11, Walter Fiedler, MD12, Elisa Cerqui, MD13*, Massimo Breccia14*, Giuseppe Fioritoni, MD15*, Helmut R Salih, MD16, Christian H. Brandts17*, Enrica Morra, MD18, Marie von Lilienfeld-Toal, MD19*, Bernd Hertenstein20*, Mohammed Wattad, MD21, Michael Lubbert, MD22, Matthias Hänel, MD23*, Norbert Schmitz, MD24, Hartmut Link, MD25*, Maria Grazia Kropp, MD26*, Alessandro Rambaldi, MD27, Giorgio La Nasa, MD28*, Mario Luppi29*, Fabio Ciceri, MD30*, Michaela Sauer31*, Hartmut Dohner, MD32, Arnold Ganser33, Franco Mandelli, MD34, Gerhard Ehninger35, Sergio Amadori, MD36*, Christian Thiede35, Richard F Schlenk, MD32 and Uwe Platzbecker, MD37

1Hematology, University Tor Vergata, Roma, Italy
2Hematology, Campus Biomedico University, Rome, Italy
3GIMEMA, Roma, Italy
4Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
5GIMEMA Data Center, GIMEMA Foundation, Roma, Italy
6GIMEMA, Rome, Italy
7Hematology, Ospedale S. Bortolo, Vicenza, Italy
8Department of Hematology, University of Bari, Bari, Italy
9Hematology, Policlinico Gemelli, Università Cattolica, Roma, Italy
10Policlinico Universitario Tor Vergata, Rome, Italy
11OSPEDALE CIVILE, Alessandria, Italy
12Hubertus Wald University Cancer Center, Department of Oncology and Hematology, University Medical Center Eppendorf, Hamburg, Germany
13Hematology Division, Spedali Civili, Brescia, Italy
14Department of Biotechnologies and Hematology, University of Rome “Sapienza”, Rome, Italy
15Hematology, Pescara, Italy
16Abteilung II für Onkologie, Hämatologie, Immunologie, Rheumatologie und Pulmologie, Medizinische Universitätsklinik Tübingen, Tübingen, Germany
17Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany
18Hematology, Niguarda Ca' Granda Hospital, Milan, Italy
19Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany
20Hämatologie und Onkologie, Klinikum Bremen Mitte, Bremen, Germany
21Kliniken Essen Süd, Essen, Germany
22University Hospital Freiburg, Freiburg, Germany
23Klinikum Chemnitz gGmbH, Chemnitz, Germany
24Abteilung f. Hämatologie, Onkologie und Stammzelltransplantation, Asklepios Klinik St. Georg Hamburg, Hamburg, Germany
25Department of Medicine I, Westpfalzklinikum, Kaiserslautern, Germany
26Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy
27Hematology, Ospedali Riuniti, Bergamo, Italy
28Department of Internal Medicine, Centro Trapianti Midollo Osseo, Ospedale R. Binaghi, Cagliari, Italy
29Bone Marrow Transplant Unit, Department of Oncology and Hematology, University of Modena, Modena, Italy
30Hematology and BMT Unit, San Raffaele Scientific Institute, Milan, Italy
31Universitatsklinikum Carl Gustav Carus, Dresden, Germany
32Internal Medicine III, University of Ulm, Ulm, Germany
33Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
34Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy
35Universitätsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
36University Tor Vergata, 00133, Italy
37Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany

Background

Simultaneous ATRA and chemotherapy (CHT) is the current gold standard for newly diagnosed APL resulting in ~80% cure rates, while arsenic trioxide (ATO) is the treatment of choice for relapsed patients. ATO in variable combinations including ± ATRA ± CHT has also been tested as front-line therapy yielding encouraging results in several pilot studies as well as in two phase III studies conducted in China and the US. So far, no randomised studies have compared front-line CHT-free ATO+ATRA combination against the standard ATRA+CHT approach.         

Patients and Methods

The phase III, randomised, prospective APL0406 trial was started in October 2007 by the Italian GIMEMA group and joined in November 2008 by the German SAL and AMLSG multicenter groups. Eligible patients were adults aged 18-<71 years with newly diagnosed, genetically confirmed, non-high-risk (WBC≤10x109/L) APL. Patients were randomized to receive the ATO+ATRA combination originally reported by the MD Anderson group (Estey et al. Blood 2006, arm A), or the Italian AIDA2000 risk-adapted protocol for non high-risk disease  (arm B). Patients in arm A received ATO 0.15/kg plus ATRA 45 mg/m2 daily until CR, then ATO 5 days/week, 4 weeks on 4 weeks off, for a total of 4 courses and ATRA 2 weeks on and 2 weeks off for a total of 7 courses. Patients in arm B received the standard AIDA (ATRA+Idarubicin) induction followed by 3 cycles of anthracycline-based plus ATRA consolidation and low dose CHT and ATRA for maintenance as reported (Lo-Coco et al., Blood 2011). The primary study objective was EFS at 2 years. The study was designed to show that the rate of patients alive event-free at two years in the experimental treatment arm is at least 80%. Secondary objectives included OS, DFS, CIR rates, molecular response and toxicity profile.     

Results

From October 2007 to September 2010, the required sample size of 162 enrolled patients was completed. Median age was 45.3 years (18.7-70.2 years) and median WBC 1.50 x 109/L. As to the Sanz’s risk score, 61.8% and 38.2% of patients were in the intermediate- and low-risk categories, respectively. The two treatment arms were well balanced for main baseline characteristics including age, sex, median WBC and Sanz’s score. Eight patients were not evaluable for induction due to ineligibility or protocol violation. Of 154 patients evaluable for response to induction, CR was achieved in 150 (97.4%): 75/75 (100%) in arm A vs 75/79 (95%) in arm B (P=0.12). After a median follow-up of 31 months (range 0.07-50.4) the 2 year EFS (primary objective) was 97% (C.I.95%: 93.1-100) and 86.7% (C.I.95%: 80.3-93.6) in arms A and B respectively (P=0.03). There were 1 death in CR and 2 relapses in arm A, and 7 deaths (4 in induction, 3 in CR) and 4 relapses in arm B. As to secondary objectives, OS, DFS, and CIR rates were 98.7% vs. 91.1% (P=0.03), 97% vs. 91.6% (P=0.19) and 1.6% vs. 4.3% (P=0.41) in arm A and B, respectively. Fever episodes, prolonged (>15 d) grade ≥ 3 neutropenia and thrombocytopenia were significantly more frequent in patients in arm B as compared to those in arm A (P <.001 for all comparisons). Other side effects including differentiation syndrome and increase of liver enzymes were recorded with similar frequency in the two study arms. Two patients in arm A had QTc prolongation requiring ATO discontinuation with final withdrawal in one case. PCR analysis of PML/RARA (sensitivity 10-4) was centrally performed in Rome (F. Lo-Coco) and Dresden (C. Thiede) and showed molecular CR in 141/142 (99%) of evaluable patients after completion of 3rd consolidation. One patient in arm B who tested PCR-positive at this time point was considered resistant and taken off protocol as per study design.     

Conclusions

For patients with newly diagnosed non-high-risk APL, as compared to the standard AIDA regimen, the front-line CHT-free ATO+ATRA combination is at least not inferior for 2 year EFS.

 

Disclosures: Lo-Coco: Boehringer Ingelheim: Membership on an entity’s Board of Directors or advisory committees; Cephalon: Speakers Bureau. Off Label Use: Arsenic Trioxide (ATO) is currently approved for therapy of relapsed APL in the US and Europe. In this study the role of ATO in front-line therapy of APL is explored. Fiedler: Pfizer Inc.: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Breccia: Celgene: Honoraria; Novartis: Honoraria; BMS: Honoraria. Platzbecker: GlaxoSmithKline: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Amgen: Consultancy.

<< Previous Abstract | Next Abstract

*signifies non-member of ASH